LYNPARZA safety checked in BRCA breast cancer survivors
NCT ID NCT05677308
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how often bone marrow suppression occurs in patients with BRCA-mutated, HER2-negative high-risk breast cancer who took LYNPARZA after surgery. It involved 61 participants in Japan. The goal was to monitor side effects in real-world use, not to measure how well the drug prevents cancer from returning.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LYNPARZA (olaparib)
What this could lead to
If successful, this study could confirm that LYNPARZA is safe enough to use as an adjuvant treatment to reduce the risk of breast cancer coming back in high-risk patients.
What could go wrong
This is a small, completed study focused on side effects, not on how well the drug works. Results may not apply to all patients, and bone marrow suppression remains a known risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Aichi, Japan
-
Research Site
Akita, Japan
-
Research Site
Aomori, Japan
-
Research Site
Chiba, Japan
-
Research Site
Ehime, Japan
-
Research Site
Fukui, Japan
-
Research Site
Fukuoka, Japan
-
Research Site
Gifu, Japan
-
Research Site
Gunma, Japan
-
Research Site
Hiroshima, Japan
-
Research Site
Hokkaido, Japan
-
Research Site
Hyōgo, Japan
-
Research Site
Ibaraki, Japan
-
Research Site
Ishikawa, Japan
-
Research Site
Kanagawa, Japan
-
Research Site
Kochi, Japan
-
Research Site
Kumamoto, Japan
-
Research Site
Kyoto, Japan
-
Research Site
Mie, Japan
-
Research Site
Miyagi, Japan
-
Research Site
Nara, Japan
-
Research Site
Niigata, Japan
-
Research Site
Numakunai, Japan
-
Research Site
Okayama, Japan
-
Research Site
Okinawa, Japan
-
Research Site
Osaka, Japan
-
Research Site
Ōita, Japan
-
Research Site
Saga, Japan
-
Research Site
Saitama, Japan
-
Research Site
Shiga, Japan
-
Research Site
Shimane, Japan
-
Research Site
Shizuoka, Japan
-
Research Site
Tochigi, Japan
-
Research Site
Tokyo, Japan
-
Research Site
Tottori, Japan
-
Research Site
Toyama, Japan
-
Research Site
Wakayama, Japan
-
Research Site
Yamaguchi, Japan